Drug Price Trends for EDARBYCLOR

Average Pharmacy Cost for EDARBYCLOR

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
EDARBYCLOR 40-12.5 MG TABLET	60631-0412-30	8.50564	EACH	2025-01-01
EDARBYCLOR 40-25 MG TABLET	60631-0425-30	8.50365	EACH	2025-01-01
EDARBYCLOR 40-25 MG TABLET	60631-0425-30	7.80144	EACH	2024-12-18
EDARBYCLOR 40-12.5 MG TABLET	60631-0412-30	7.80327	EACH	2024-12-18

Market Analysis and Price Projections for EDARBYCLOR

Introduction to EDARBYCLOR

EDARBYCLOR, a fixed-dose combination of azilsartan medoxomil and chlorthalidone, is a potent medication designed to treat hypertension. It combines an angiotensin II receptor blocker (ARB) with a thiazide diuretic, making it an effective option for managing high blood pressure in various patient populations[4][5].

Market Size and Growth

The market for EDARBYCLOR is part of the broader hypertension treatment market, which is expected to grow significantly due to increasing prevalence of hypertension and other cardiovascular diseases. The Edarbi market, which includes EDARBYCLOR, is projected to expand at a considerable growth rate during the forecast period from 2022 to 2028. This growth is driven by factors such as increasing awareness about hypertension, the importance of early diagnosis, and growing spending on chronic diseases[3].

Key Market Drivers

• Increasing Prevalence of Hypertension: The rising number of patients with hypertension globally is a significant driver for the EDARBYCLOR market. As more people are diagnosed and treated for high blood pressure, the demand for effective medications like EDARBYCLOR increases.
• Research and Development: Continuous investment in research and development by key players in the market is leading to the creation of technologically advanced products, which in turn boosts market growth[3].
• Market Penetration: Efforts to increase market penetration, especially in developing regions, offer lucrative growth opportunities despite challenges such as limited awareness and high costs[3].

Market Challenges

• High Cost: The cost of EDARBYCLOR is a significant barrier, especially for cash-paying customers. A 30-tablet supply of EDARBYCLOR can cost around $266, which is a substantial expense for many patients[2].
• Limited Awareness: In some regions, particularly developing countries, there is limited awareness about hypertension and the available treatments, which can restrict the adoption of EDARBYCLOR.
• Insurance and Economic Factors: The lack of favorable insurance systems and low economic conditions in some areas further hinder the widespread adoption of EDARBYCLOR[3].

Clinical Efficacy and Patient Populations

EDARBYCLOR has demonstrated superior efficacy in clinical studies compared to other similar medications. Here are some key points:

• Superior Blood Pressure Control: EDARBYCLOR has shown statistically superior blood pressure control when compared to Benicar HCT (olmesartan medoxomil-hydrochlorothiazide) in clinical studies. It achieved a 14.5% greater reduction in systolic blood pressure[1][4].
• Effectiveness in African American Patients: EDARBYCLOR is particularly effective in treating African American patients, who often have a less active renin-angiotensin system (RAS). It provided an 18% greater systolic blood pressure reduction compared to Benicar HCT in this patient subgroup[1][4].

Pricing and Cost Considerations

• Current Pricing: The cost for a 30-tablet supply of EDARBYCLOR (40 mg-12.5 mg or 40 mg-25 mg) is approximately $266, depending on the pharmacy and location[2].
• Discounts and Assistance Programs: Patients can use discount cards, such as the Drugs.com discount card, to reduce the cost. However, generic versions of EDARBYCLOR are not yet available, which can limit affordability for some patients[2].

Licensing and Distribution

EDARBYCLOR is marketed and sold in the United States by Arbor Pharmaceuticals under a licensing agreement with Takeda Pharmaceuticals. This agreement allows Arbor to promote and sell EDARBYCLOR exclusively in the U.S., while Takeda receives upfront payments and future milestone and royalty payments based on sales[5].

Future Outlook

Given the increasing prevalence of hypertension and the demonstrated efficacy of EDARBYCLOR, the market for this medication is expected to grow. Here are some key projections:

• Market Growth Rate: The Edarbi market, including EDARBYCLOR, is expected to grow at a considerable CAGR from 2022 to 2028[3].
• Revenue Forecast: The revenue forecast for the Edarbi market is expected to increase significantly by 2028, driven by growing demand and increased market penetration[3].
• Regional Expansion: The market is expected to expand across various regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa[3].

Key Takeaways

• Efficacy: EDARBYCLOR has shown superior blood pressure control compared to similar medications.
• Market Growth: The market for EDARBYCLOR is expected to grow due to increasing prevalence of hypertension and ongoing research and development.
• Pricing: The current cost of EDARBYCLOR is around $266 for a 30-tablet supply, with no generic version available.
• Distribution: EDARBYCLOR is marketed and sold in the U.S. by Arbor Pharmaceuticals under a licensing agreement with Takeda.

FAQs

1. What is EDARBYCLOR used for?

   • EDARBYCLOR is used for the treatment of hypertension in adults to lower blood pressure. It can be used as an initial therapy or in patients not adequately controlled with monotherapy[5].

2. How does EDARBYCLOR compare to other hypertension medications?

   • EDARBYCLOR has demonstrated statistically superior blood pressure control compared to Benicar HCT in clinical studies, especially in African American patients[1][4].

3. What are the common side effects of EDARBYCLOR?

   • Clinical studies have shown that the side effects of EDARBYCLOR are generally mild and transient. Patients may need monitoring of potassium and creatinine levels while taking the medication[4].

4. Is EDARBYCLOR available as a generic?

   • No, EDARBYCLOR is currently available only as a brand name drug, and a generic version is not yet available[2].

5. Who markets and sells EDARBYCLOR in the United States?

   • EDARBYCLOR is marketed and sold in the United States by Arbor Pharmaceuticals under a licensing agreement with Takeda Pharmaceuticals[5].

Sources

1. EDARBYCLOR® (azilsartan medoxomil/chlorthalidone) Efficacy - Edarbi.com
2. Edarbyclor Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
3. Edarbi Market Size, Global Forecast to 2028 - Eternity Insights
4. EDARBYCLOR® once daily high blood pressure treatment - Edarbi.com
5. Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR - PR Newswire